Indium (111In) biciromab

Indium (111In) biciromab (INN, trade name FibriScint, developed by Centocor) was a drug targeting fibrin, a protein involved in the clotting of blood.[1] It was the Fab' fragment of a mouse monoclonal antibody labelled with the radioisotope indium-111 for the diagnosis of thromboembolism,[2] but was withdrawn during clinical trials.[3]

Indium (111In) biciromab
Monoclonal antibody
TypeFab' fragment
SourceMouse
TargetFibrin II, beta chain
Clinical data
Trade namesFibriScint
Pregnancy
category
  • N/A
ATC code
  • none
Legal status
Legal status
  • Withdrawn
Identifiers
CAS Number
ChemSpider
  • none
KEGG
 NY (what is this?)  (verify)

References
  1. King DJ, Adair JR (March 1999). "Recombinant antibodies for the diagnosis and therapy of human diseases". Current Opinion in Drug Discovery & Development. 2 (2): 110–7. PMID 19649936.
  2. "Centocor Ortho Biotech Products, L.P." Answers.com.
  3. "Centocor withdraws imaging agent applications". DiagnosticImaging.com.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.